Trial Profile

A phase 1/2 trial of EO2401, a novel microbial-derived peptide therapeutic vaccine, in combination with PD-1 check point blockade, for treatment of patients with locally advanced or metastatic adrenocortical carcinoma, or malignant pheochromocytoma/paraganglioma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 05 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EO 2401 (Primary) ; Nivolumab (Primary)
Indications Adrenal cancer; Adrenocortical carcinoma; Cancer metastases; Liver metastases; Paraganglioma; Phaeochromocytoma
Focus Adverse reactions; First in man
Acronyms EOADR1-19; EOADR1-19/SPENCER; Spencer
Sponsors Enterome

30 Jan 2026 Actual primary completion date changed from 30 May 2024 to 2 Oct 2024.
12 Nov 2024 Status changed from active, no longer recruiting to discontinued.
17 Jul 2024 This trial has been completed in Germany, according to European Clinical Trials Database

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com